1-20 of 22
Keywords: Sumatriptan
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Eur Neurol (1994) 34 (Suppl. 2): 35–39.
Published Online: 27 February 2008
...Peter J. Goadsby Cluster headache is a rare form of severe idiopathic headache characterized by unilateral short-lasting episodes of excruciating pain in association with autonomic disturbances. Subcutaneous sumatriptan has been investigated as an acute treatment for cluster headache in two...
Journal Articles
Eur Neurol (1994) 34 (Suppl. 2): 18–25.
Published Online: 27 February 2008
... trials undertaken with defined diagnostic criteria and study end-points. Analgesics with anti-emetics, nonsteroidal anti-inflammatory drugs and ergot derivatives are used for acute treatment. Recently, the selective 5-HT 1 receptor agonist sumatriptan has become available and been shown to have...
Journal Articles
Eur Neurol (1994) 34 (Suppl. 2): 40–43.
Published Online: 27 February 2008
...Kate Lloyd The safety and tolerability of sumatriptan have been extensively studied. The majority of adverse events (defined as any medical event irrespective of possible causal relationship to treatment) were mild to moderate in intensity, transient and resolved spontaneously. In short-term...
Journal Articles
Eur Neurol (1994) 34 (Suppl. 2): 26–34.
Published Online: 27 February 2008
...Alison J. Pilgrim The efficacy of the 5-HT 1 receptor agonist sumatriptan in the acute treatment of migraine has been investigated in an extensive programme of controlled clinical trials. Sumatriptan provided rapid relief from migraine headache with onset of relief occurring within 10 min of a 6 mg...
Journal Articles
Eur Neurol (1992) 32 (3): 177–184.
Published Online: 12 February 2008
... In a double-blind, placebo-controlled study, the efficacy, safety and tolerability of 100 mg oral sumatriptan, given as a dispersible tablet, was compared with that of 900 mg oral aspirin plus 10 mg oral metoclopramide in the acute treatment of migraine. A total of 358 patients treated up to three...
Journal Articles
Eur Neurol (1993) 33 (4): 310–315.
Published Online: 12 February 2008
...M.J.B. Tansey; A.J. Pilgrim; P.M. Martin Sumatriptan, a specific 5-hydroxytryptamine agonist, is a novel acute treatment for migraine. The efficacy and safety profiles of sumatriptan have previously been demonstrated in several controlled short-term studies. However, because migraine is a recurrent...
Journal Articles
Eur Neurol (1995) 35 (5): 264–269.
Published Online: 12 February 2008
...F. Boureau; G. Chazot; J. Emile; L. Bertin; H. d’Allens 246 migraine patients (International Headache Society definition, 1-6 severe attacks per month) were randomised into a multicentre, cross-over study comparing subcutaneous (s.c.) sumatriptan 6 mg administered by an auto-injector (Glaxo device...
Journal Articles
Journal Articles
Eur Neurol (1991) 31 (5): 339–344.
Published Online: 08 February 2008
...E.G. Brown; C.A. Endersby; R.N. Smith; J.C.C Talbot Safety information was pooled from 4,859 patients, mainly treated in controlled clinical trials with a dispersible tablet of sumatriptan or by a subcutaneous injection, and from 1,164 patients who received placebo by these routes. Safety...
Journal Articles
Eur Neurol (1991) 31 (5): 291–294.
Published Online: 08 February 2008
... was rapid. Bioavailability was nearly 100% after subcutaneous administration and averaged 14% after oral administration. Elimination was predominantly by metabolism to a non-active indoleacetic acid analogue. The plasma half-lives of sumatriptan and the metabolite were about 2 h. Pharmacokinetic...
Journal Articles
Journal Articles
Eur Neurol (1991) 31 (5): 300–305.
Published Online: 08 February 2008
... Three oral doses of sumatriptan, 100, 200 and 300 mg, given as dispersible tablets, were compared in the acute treatment of migraine in a double-blind, placebo-controlled, parallel-group study of 1,130 patients from 51 centres in eight countries. Patients treated up to three migraine attacks...
Journal Articles
Eur Neurol (1991) 31 (5): 295–299.
Published Online: 08 February 2008
...A.J. Pilgrim The clinical development of sumatriptan has involved large international multicentre trials. To allow comparison of results obtained in a variety of clinical settings, great emphasis was placed on the use of consistent methodology across the programme. This applied to selection...
Journal Articles
Journal Articles
Eur Neurol (1991) 31 (5): 279–281.
Published Online: 08 February 2008
...-effects of nausea, faintness, paraesthesia and dyspnoea. The 5-HT 1 -like agonist sumatriptan exerts the beneficial effects of 5-HT with minimal side-effects. Receptors for 5-HT are present in cranial arteries and are also widely distributed in the central nervous system, where they play a role...
Journal Articles
Journal Articles
Eur Neurol (1991) 31 (5): 282–290.
Published Online: 08 February 2008
...P.P.A. Humphrey; W. Feniuk; A.S. Marriott; R.J.N. Tanner; M.R. Jackson; M.L. Tucker Sumatriptan is believed to constrict selectively the cranial vessels that are distended and inflamed during migraine. The action is mediated by activation of a 5-HT 1 receptor subtype which has been shown in animals...
Journal Articles
Journal Articles
Eur Neurol (2005) 53 (Suppl. 1): 41–48.
Published Online: 23 May 2005
...Hans-Christoph Diener; Astrid Gendolla; Irmingard Gebert; Manfred Beneke Objective: To investigate the efficacy and tolerability of almotriptan 12.5 mg in migraine patients who respond poorly to sumatriptan 50 mg. Background: Poor response to sumatriptan therapy for acute migraine attacks has been...
Journal Articles